# Long Term Safety of SL77.0499-10 (Alfuzosin) in Patients With BPH

> **NCT00347061** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 148 (actual)

## Conditions studied

- Benign Prostatic Hyperplasia

## Interventions

- **DRUG:** afuzosin

## Key facts

- **NCT ID:** NCT00347061
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2007-10
- **Final completion:** 2007-10
- **Target enrollment:** 148 (ACTUAL)
- **Last updated:** 2009-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00347061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00347061, "Long Term Safety of SL77.0499-10 (Alfuzosin) in Patients With BPH". Retrieved via AI Analytics 2026-08-22 from https://api.ai-analytics.org/clinical/NCT00347061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*